key: cord-1045929-zhdjygi1
authors: Abraham, Natalia; Spruin, Sarah; Rossi, Tanya; Fireman, Bruce; Zafack, Joseline; Blaser, Christine; Shaw, Amanda; Hutchings, Kimberley; Ogunnaike-Cooke, Susanna
title: Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: a Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines
date: 2022-05-25
journal: Vaccine
DOI: 10.1016/j.vaccine.2022.05.048
sha: 1b8191d36c9c905f2fe6a18738e9448281acd072
doc_id: 1045929
cord_uid: zhdjygi1

BACKGROUND: Canadian and international data suggest the risk of myocarditis and/or pericarditis is elevated during the week after mRNA COVID-19 vaccination, particularly in younger age groups, in males, and after second doses. OBJECTIVES: This article examines whether there is a product-specific difference in the risk for myocarditis and/or pericarditis between the two mRNA vaccines administered in Canada: BNT162b2 (Pfizer-BioNTech Comirnaty) and mRNA-1273 (Moderna Spikevax). MATERIALS AND METHODS: Reporting rates of myocarditis and/or pericarditis were calculated from reports received by the Canadian Adverse Events Following Immunization Surveillance System from December 2020-March 2022. Excess cases and attributable incidence among individuals aged 18-39 were estimated for each vaccine in comparison with background rates from 2015–2019. Head-to-head comparisons used Poisson regression, conditioned on week of vaccine administration, to estimate rate ratios for the week after mRNA-1273 vaccination versus the week after BNT162b2, by age and sex as well as overall. Analyses were restricted to May 30–March 13, 2021, when heightened media awareness was unlikely to have affected reporting rates for the two products differentially. RESULTS: In 18-29 year-old males who received a second dose of mRNA COVID-19 vaccine, attributable risk of myocarditis and/or pericarditis was found to be 5.69 (95% CI: 4.07 – 7.95; p < 0.001) times higher among mRNA-1273 recipients (n=106) as compared to BNT162b2 recipients (n=33). In the same group, Poisson regression modelling estimated that the risk of myocarditis and/or pericarditis was 4.72 (p-value = <0.001) times higher after mRNA-1723 compared to BNT162b2 vaccination. CONCLUSIONS: The risk of myocarditis and/or pericarditis is higher after mRNA-1723 vaccination than BNT162b2 vaccination in those aged 18-39 years, especially in males aged 18-29 years, where the risk is several times higher.

Objectives: This article examines whether there is a product-specific difference in the risk for 33 myocarditis and/or pericarditis between the two mRNA vaccines administered in Canada: BNT162b2 34 (Pfizer-BioNTech Comirnaty) and mRNA-1273 (Moderna Spikevax). other countries detected a disproportionate number of reports of myocarditis and/or pericarditis 6 (inflammation of the heart muscle and/or lining of the heart muscle) that had not been picked up during 7 clinical trials [3, 4] , occurring very rarely but with higher frequency than expected during the week after 8 mRNA vaccination, especially in younger age groups, in males, and after the second dose [5] [6] [7] [8] . National 9 immunization technical advisory groups (NITAG) around the world subsequently deliberated on the risk-10 benefit of mRNA vaccination in younger age groups. They took into consideration the relatively low 11 burden of SARS-CoV-2 infection in these age strata [9, 10] and early data suggesting that, particularly in 12 younger age groups, myocarditis and/or pericarditis following immunization was largely self-limited and 13 without short-term complication, though a range of severity was noted and follow-up time was limited 14 [5] [6] [7] [8] . 15 16 In early June 2021, the Public Health Agency of Canada and Health Canada sent a series of communiques 17 out to health care professionals for awareness and guidance. Health Canada authorized updated 18 product monographs of both mRNA COVID-19 vaccines to include information about these risks (30 19 June, 2021) [11] . Canada's National Advisory Committee on Immunization (NACI) first added information 20 on myocarditis and/or pericarditis in its guidance on June 17 and on July 2, 2021, it recommended that a 21 complete series with BNT162b2 should be offered to individuals 12 to 15 years of age without 22 contraindications to the vaccine, noting that informed consent should include a discussion about very 23 rare reports of myocarditis and/or pericarditis following an mRNA dose [12] . 24 25

Publicly available US [13, 14] and Canadian [15] reporting rates of myocarditis and/or pericarditis risk are 26 inconsistent on whether there is a product-specific difference in risk between the two mRNA vaccines, 27 and this has garnered attention internationally [16] . Surveillance data in France found statistically 28 significantly higher rates of myocarditis and/or pericarditis following dose 2 mRNA-1273 vaccination 29 than BNT162b2 vaccination in males aged 18-29 years of age [17] , results which were mirrored in a case 30 control study also conducted in France [18] . week only to the best model conditioned on both week and jurisdiction. Statistical analysis was 181 performed using the R statistical software "gnm" and "stats" packages [35, 36] . After testing all possible interactions (i.e., age group and vaccine type, sex and vaccine type, and age 247 group and sex), the interaction between age group and sex was the only interaction found to improve 248 the model fit based on a likelihood ratio test ( Table 3) . The model including a three-way interaction 249 between age group, sex, and vaccine was not found to be superior to the model including the two-way 253 254

The superior model, which contained an interaction term for age group and sex, found the risk of 255 myocarditis and/or pericarditis following dose 2 of mRNA-1273 vaccine to be 4.14 times higher than the 256 risk following dose 2 of the BNT162b2 (Table 3) . Stratified conditional Poisson models by age group and 257 sex were also run. There were a total of 217 reports in those aged 18-29 of myocarditis and/or 258 pericarditis following dose 2 of an mRNA vaccine (86% male), and 65 in those aged 30-39 (62% male). provided critical review. We would also like to thank each and every individual who takes the time to 405

submit an AEFI report for their contribution to vaccine safety in Canada. 

Moderna Spikevax COVID-19 vaccine [Internet]. Government of Canada

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination

Myocarditis Temporally Associated With COVID-19 Vaccination

Myocarditis With COVID-19 mRNA Vaccines

Myocarditis and Pericarditis After Vaccination for COVID-19

If Young Children's Risk of SARS-CoV-2 Infection Is Similar to That of Adults, Can Children Also Contribute to Household Transmission? JAMA Pediatrics

Hospitalization Rates and Characteristics of Children Aged 18 Years Hospitalized with Laboratory-Confirmed COVID-19 -COVID-NET, 14 States

Health Canada updates Pfizer-BioNTech and Moderna COVID-19 vaccine labels to include information on myocarditis and pericarditis

Public Health Agency of Canada. Recommendations on the use of COVID-19 vaccines

Myocarditis Analyses in the Vaccine Safety Datalink: Rapid Cycle Analyses and "Head-to-Head" Product Comparisons

Myopericarditis following COVID-19 vaccination: Updates from the Vaccine Adverse Event Reporting System (VAERS)

COVID-19 vaccine safety: Weekly report on side effects following immunization

officials investigate whether Moderna vaccine is linked to higher risk of uncommon side effect than previously thought

Anchorage Daily News

Enquête de pharmacovigilance du vaccin Pfizer -BioNTech Comirnaty Focus mensuel n°1 situations spécifiques jusqu'au 30 septembre 2021

Association entre les vaccins COVID-19 à ARN messager et la survenue de myocardite et péricardite chez les personnes de 12 à 50 ans en France Etude à partir des données du Système National des Données de Santé (SNDS)

Vaccination 600 % plus élevée dans les réserves autochtones qu'ailleurs au pays

COVID-19 in Indigenous communities: 75% of First Nations and Inuit adults have had 1st vaccine dose | CBC News

Canada's eight-component vaccine safety system: A primer for health care workers

Canadian Adverse Events Following Immunization Surveillance System (CAEFISS)

Brighton Collaboration Myocarditis Case Definition (Pandemic Emergency Response Process_Draft Release

Public Health Agency of Canada. COVID-19 vaccination coverage surveillance system (CCVCSS)

Government of Canada

Vigie des activités de vaccination contre la COVID-19 et de suivi des couvertures vaccinales au Québec

Package "epitools

Discharge Abstract Database, Canadian Institute for Health Information, fiscal years

National Ambulatory Care Reporting System, Canadian Institute for Health Information, fiscal years

Canadian Institute for Health Information. Provincial/Territorial Data Quality Report: Indicators and Contextual Measures -Reference Guide

ACCESS-Background rate of adverse eventsdefinition -Myocarditis and/or pericarditis

Table 17-10-0005-01 Population estimates on July 1st, by age and sex

Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines

Conditional Poisson models: a flexible alternative to conditional logistic case cross-over analysis

The R Stats Package

Myocarditis and Pericarditis Following Vaccination with COVID-19 mRNA Vaccines in Ontario

COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS): updated statement regarding myocarditis and pericarditis reported with COVID-19 mRNA vaccines

Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination -PCORnet

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection

Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data -United States

Risk of Myocarditis from COVID-19 Infection in People Under Age 20: A Population-Based Analysis

Clinically Suspected and Biopsy-Proven Myocarditis Temporally Associated with SARS-CoV-2 Infection

Prevalence of Clinical and Subclinical Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection: Results From the Big Ten COVID-19 Cardiac Registry

Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis. The Lancet Respiratory Medicine

Shedding the Light on Post-Vaccine Myocarditis and Pericarditis in COVID-19 and Non-COVID-19 Vaccine Recipients. Vaccines

Epidemiological Impact of Myocarditis

Vaccine vigilance in Canada: Is it as robust as it could be? Can Commun Dis Rep

Centers for Disease Control and Prevention. ACIP Live Meeting Archive -February

National Advisory Committee on Immunization. Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 to 11 years of age

Public Health Agency of Canada